Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP, Chief Legal Officer | August 05, 2021 | August 09, 2021 |
| Immuneering CorpIMRX · Entity 5884 | Director | June 11, 2026 | June 11, 2026 |
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | August 01, 2026 | August 03, 2026 |
| PepGen Inc.PEPG · Entity 6253 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date August 05, 2021 · Filed August 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,132 |
Ending reported balance
After 2021-08-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-08-05 · Exercise / conversion · Acquired 7,876 · Balance 13,008 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Row 2 · 2021-08-05 · Exercise / conversion · Acquired 2,124 · Balance 15,132 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Row 3 · 2021-08-05 · Sale · Disposed 10,000 · Balance 5,132 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. |
| Performance Stock Option 2015 (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.95 · Expires 2025-12-18 | Direct | 11,876 |
Reported balance
After 2021-08-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-05 · Exercise / conversion · Disposed 2,124 · Balance 11,876 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.95 · Expires 2025-12-18 | Direct | 1,124 |
Reported balance
After 2021-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-05 · Exercise / conversion · Disposed 7,876 · Balance 1,124 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. F3: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 434 |
Reported balance
Holding disclosure · report date 2021-08-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 434 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F3: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Immuneering Corp
Report date June 11, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11 | Direct | 33,350 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.
Kalaris Therapeutics, Inc.
Report date August 01, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2036-07-31 | Direct | 18,000 |
Reported balance
After 2026-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-01 · Grant · Acquired 18,000 · Balance 18,000 F1: The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.
PepGen Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2036-06-17 | Direct | 34,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 34,000 · Balance 34,000 F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Imago BioSciences, Inc.
Report date January 11, 2023 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.76 · Expires 2031-11-16 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-11 · Disposition to issuer · Disposed 23,809 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.65 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-11 · Disposition to issuer · Disposed 11,904 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2021 Filed Jan 13, 2021 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,000 | $165.00 | $495,000.00 |
DisclosureSEC source: 0001735276-21-000004 · edgardoc.xml · nonDerivative · entry 5 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,234 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 11,941 | $159.00 | $1,898,619.00 |
DisclosureSEC source: 0001735276-21-000004 · edgardoc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,234 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 13,000 | $77.40 | $1,006,200.00 |
DisclosureSEC source: 0001735276-21-000004 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,941 | $42.22 | $81,949.02 |
DisclosureSEC source: 0001735276-21-000004 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 758 | $154.00 | $116,732.00 |
DisclosureSEC source: 0001735276-21-000004 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,234 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · derivative · entry 15 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 6,250 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F10 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 23,809 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · derivative · entry 14 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,191 Underlying: Common Stock · 23,809 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F9 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,941 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · derivative · entry 13 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 Underlying: Common Stock · 1,941 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F9 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2017 (right to buy) · Derivative | 3,750 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · derivative · entry 12 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 3,750 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9,530 | $162.24 | $1,546,147.20 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 10 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F7 · price: Sale prices ranged from $161.91 to $162.80. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15,618 | $161.32 | $2,519,495.76 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 9 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,522 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F6 · price: Sale prices ranged from $160.90 to $161.89. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14,236 | $160.52 | $2,285,162.72 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 8 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,140 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F5 · price: Sale prices ranged from $159.89 to $160.86. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,061 | $159.22 | $168,932.42 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 7 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,376 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F4 · price: Sale prices ranged from $158.82 to $159.64. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,323 | $158.27 | $367,661.21 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 6 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,437 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F3 · price: Sale prices ranged from $157.74 to $158.62. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,482 | $157.16 | $704,391.12 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 5 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,760 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. F2 · price: Sale prices ranged from $156.86 to $157.66. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,250 | $119.13 | $744,562.50 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,750 | $119.13 | $446,737.50 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 23,809 | $77.40 | $1,842,816.60 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,941 | $42.22 | $81,949.02 |
DisclosureSEC source: 0001735276-20-000090 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2020. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001735276-20-000056 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 10,000 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,000 | $139.00 | $1,390,000.00 |
DisclosureSEC source: 0001735276-20-000056 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,492 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $77.40 | $774,000.00 |
DisclosureSEC source: 0001735276-20-000056 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 75 | $105.63 | $7,922.25 |
DisclosureSEC source: 0001735276-20-000047 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,492 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 1,858 | $104.75 | $194,625.50 |
DisclosureSEC source: 0001735276-20-000047 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,567 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000047 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,425 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 24,554 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-20-000033 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,554 Underlying: Common Stock · 24,554 shares Expires 2030-02-25 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 13,554 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001735276-20-000014 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 10,000 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,000 | $129.00 | $1,290,000.00 |
DisclosureSEC source: 0001735276-20-000014 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,258 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $77.40 | $774,000.00 |
DisclosureSEC source: 0001735276-20-000014 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 6,337 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001735276-20-000004 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 6,337 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,337 | $119.00 | $754,103.00 |
DisclosureSEC source: 0001735276-20-000004 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,595 Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,337 | $77.40 | $490,483.80 |
DisclosureSEC source: 0001735276-20-000004 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 3,663 | $0.00 Strike: $77.40 | $0.00 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · derivative · entry 12 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,337 Underlying: Common Stock · 3,663 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 9,374 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · derivative · entry 11 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,252 Underlying: Common Stock · 9,374 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 25,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · derivative · entry 10 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 190 | $120.21 | $22,839.90 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 8 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,595 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F7 · price: Sale prices ranged from $120.20 to $120.22 Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,667 | $119.53 | $796,906.51 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 7 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,785 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F6 · price: Sale prices ranged from $119.16 to $120.04 Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 13,084 | $118.61 | $1,551,893.24 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 6 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,452 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F5 · price: Sale prices ranged from $118.15 to $119.12 Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,100 | $117.67 | $482,447.00 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 5 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,536 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F4 · price: Sale prices ranged from $117.10 to $118.10 Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 13,631 | $116.43 | $1,587,057.33 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,636 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F3 · price: Sale prices ranged from $116.04 to $117.04 Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,365 | $115.55 | $388,825.75 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,267 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · price: Sale prices ranged from $115.03 to $116.03 Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 25,000 | $42.22 | $1,055,500.00 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 9,374 | $42.22 | $395,770.28 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 27, 2020 Filed Feb 12, 2020 21:02 UTC Amendment | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,663 | $77.40 | $283,516.20 |
DisclosureSEC source: 0001735276-20-000013 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was made pursuant to Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Reflects shares acquired upon the exercise by the reporting person of a stock option on January 27, 2020. This acquisition was inadvertently omitted from the Form 4 filed on January 29, 2020 which reported both the exercise of the stock option and the subsequent sale of such acquired shares. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 4,583 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000121 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,166 Underlying: Common Stock · 4,583 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 4,583 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000109 · edgardoc.xml · derivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 Underlying: Common Stock · 4,583 shares Expires 2028-03-01 F2 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| October 10, 2019 Filed Nov 26, 2019 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000109 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 434 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000086 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F3 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-19-000086 · edgardoc.xml · derivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F2 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| July 11, 2019 Filed Aug 7, 2019 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000086 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 424 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.